Oncolytics Biotech
@Oncolytics
Followers
3K
Following
86
Statuses
2K
Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells. Contact company: https://t.co/sNAsxxiOi5
Calgary, Alberta
Joined March 2009
Today is #WorldCancerDay. At Oncolytics, we are working to harness the power of #immunotherapy to advance science and bring a potential new treatment option to patients with #cancer. Learn how you can support World Cancer Day here:
0
4
4
Check out this @Labiotech article by @willowshahnev, which highlights the urgent need for new #PancreaticCancer treatments and provides an overview of our work to advance our #immunotherapy through the clinic. Read it here:
0
1
2
Last week at #BiotechShowcase, our CMO, Thomas Heineman, MD, PhD, presented the latest on #pelareorep, highlighting our clinical progress and potential to transform #cancer care. We are excited for 2025 as we continue advancing this #immunotherapy for patients.
0
3
5
We will present posters at @ASCO’s #GI25 highlighting new data from GOBLET, a #ClinicalTrial evaluating our #immunotherapy in #PancreaticCancer and #AnalCancer. Read more about the results here:
0
0
3
Today we shared that @PEI_Germany approved our plans to move to full enrollment of 30 patients in cohort 5 of GOBLET, our #PancreaticCancer #ClinicalTrial in collaboration with @AIO_Onkologie and @PanCAN: #Immunology
0
0
2
As 2024 comes to an end, we're proud of our progress this year, including promising BRACELET-1 results in HR+/HER2- metastatic #BreastCancer and advances in our gastrointestinal #cancer program with #pelareorep. Read more about our progress and 2025 plans:
0
3
5
Today, we announced our team will present new #pelareorep data at #ASCOGI in two presentations to highlight its potential in difficult-to-treat #PancreaticCancer and #AnalCancer. More on the abstracts here: @ASCO #GI25 #oncology #CancerResearch #biotech
0
2
4
#PancreaticCancerAwarenessMonth recently ended, but our efforts with groups like @PanCAN and @AIO_Onkologie continue. Enrollment is complete for the safety run-in of the GOBLET #PancreaticCancer cohort evaluating #pelareorep + mFOLFIRINOX +/- atezolizumab
0
0
2
RT @Xtalks: In this episode, hear about the work Dr. Heineman is leading at Oncolytics Biotech in the development of oncolytic virus therap…
0
2
0
RT @PanCAN: IT'S WORLD PANCREATIC CANCER DAY! 💜📣🎗 Let's turn the world purple today to show support for those facing this disease! Here's…
0
55
0
RT @GCAResearch: Behind the scenes, GCAR is working hard to finalize the Pancreatic Cancer Master Protocol trial design. Earlier this year…
0
1
0
Our Q3 #earnings call shared BRACELET-1 data in HR+/HER2- metastatic #BreastCancer, supporting #pelareorep with paclitaxel for a registrational study. Upcoming GOBLET milestones include #AnalCancer efficacy and #PancreaticCancer safety data. More here:
0
1
2
Please join us tomorrow morning Nov. 12 for our Q3 financial results and corporate update, details in the PR below: #biotech #earnings #immunotherapy #CancerResearch #BreastCancer #PancreaticCancer #oncology
0
1
2
Today we #WearItPink to bring awareness to #BreastCancer during #BreastCancerAwarenessMonth. #WearItPinkDay #BreastCancerAwareness
0
0
1
Today we shared updates from the #ClinicalTrials of our #immunotherapy candidate for #BreastCancer & #PancreaticCancer. We look forward to advancing these studies and potentially bringing new treatments to patients in need. More here: #CancerResearch
0
3
12
Our CMO, Tom Heineman, joined Hüseyin Kandemir of @HealthNDPharma on an episode on ONCOLife to discuss the future of oncolytic viruses and our #ClinicalTrial in #MetastaticBreastCancer. What here: #BreastCancer #BreastCancerResearch #biotech
0
1
3
We are driven by the opportunity to improve the lives of people with #cancer. Results from the BRACELET-1 trial showed improved survival in patients with HR+/HER2- metastatic #BreastCancer. Check out our updated webpage highlighting the data here: #biotech
0
0
3
Our management team had a great fireside chat at the #CantorHCC earlier today. We discussed the impressive #pelareorep BRACELET-1 #BreastCancer data, #PancreaticCancer, and the work we're doing with @GCAResearch and @PanCAN. Catch the replay here: #biotech
0
3
5
RT @TargetedOnc: Findings from the phase 2 BRACELET-1 trial showed that pelareorep + paclitaxel significantly improved outcomes in HR+/HER2…
0
2
0
Today, we announced positive results from BRACELET-1, our randomized Phase 2 study evaluating #pelareorep in patients with HR+/HER2- metastatic #BreastCancer. These include an estimated 14-month OS benefit and 5.7-month PFS benefit, more details in the PR:
0
1
2